SCHEMBL22275990

SCHEMBL22275990

COc1ncc(-c2n[nH]c3ncnc(N)c23)cn1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 9/20 0.39
PIK3CA P42336 9/20 0.39
PIK3CB P42338 9/20 0.39
PIK3CG P48736 9/20 0.39
PRKDC P78527 9/20 0.39
SRC P12931 9/20 0.39
ABL1 P00519 8/20 0.39
EGFR P00533 8/20 0.39
HCK P08631 8/20 0.39
MTOR P42345 8/20 0.39
EPHB4 P54760 8/20 0.39
PI4KB Q9UBF8 7/20 0.39
PLAU P00749 1/20 0.38
KDR P35968 9/20 0.36
MAPK1 P28482 3/20 0.36
MAP4K4 O95819 1/20 0.36
DYRK1B Q9Y463 1/20 0.35
TEK Q02763 1/20 0.35
FYN P06241 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20794098 0.80 PIK3CD (0.57) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20093453 0.80 PIK3CD (0.46) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL149528 0.79 KDR (0.52) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL19414400 0.79 CYP1A1 (0.47) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20093480 0.79 LRRK2 (0.39) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16783676 0.78 BACE1 (0.40) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL19414291 0.77 SRC (0.40) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20640210 0.77 CFTR (0.36) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL149180 0.76 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL11975 0.76 PIK3CB (0.39) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 PIK3CD 288/4885PIK3CA 221/4885PIK3CB 248/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.